Average Insider

Where insiders trade, we follow

$IVVD
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
William E. Duke Jr.
CEO
99
Employees
$0.80
Current Price
$505.68M
Market Cap
52W Low$0.53
Current$0.8010.9% above low, 89.1% below high
52W High$3.07

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00---
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Aug 18, 2026
Lee Timothy Edward
Chief Commercial Officer
Sale18,425$0.84$15,530.43View Details
Aug 18, 2026
Green Julie
Chief Human Resources Officer
Sale18,425$0.84$15,530.43View Details
Aug 18, 2026
Duke William E.
Chief Financial Officer
Sale18,425$0.84$15,530.43View Details
Aug 18, 2026
Andersen Jill
Chief Legal Officer, Secretary
Sale30,706$0.84$25,882.09View Details
Aug 18, 2026
Allen Robert D. III
Chief Scientific Officer
Sale17,043$0.84$14,365.54View Details
16 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 16, 2026
EPS
Estimated-$0.13
Actual-$0.10
Beat
Revenue
Estimated$15.04M
Actual$15.45M
Beat
Nov 13, 2026
EPS
Estimated-$0.13
ActualN/A
Revenue
Estimated$15.04M
ActualN/A
Nov 12, 2026
EPS
Estimated-$0.13
ActualN/A
Revenue
Estimated$15.04M
ActualN/A
Nov 9, 2026
EPS
Estimated-$0.13
ActualN/A
Revenue
Estimated$15.04M
ActualN/A
Nov 5, 2026
EPS
Estimated-$0.11
ActualN/A
Revenue
Estimated$15.04M
ActualN/A
1 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1